Peroxisome Proliferator-Activated Receptors as New Molecular Targets in Psoriasis

Author(s): Stephane Kuenzli, Jean-Hilaire Saurat

Journal Name: Current Drug Targets - Inflammation & Allergy
Continued as Inflammation & Allergy - Drug Targets

Volume 3 , Issue 2 , 2004


While psoriasis is upon the age of biological treatments, additional researches have led to other new therapies for psoriasis, including targets aimed at nuclear receptors. PPARs are members of the nuclearhormone- receptor superfamily, including retinoid receptors and vitamin D receptors. Recent works have highlighted the role of PPARs, which transduce a wide variety of signals into a set of cellular responses at the level of gene transcription, as critical regulators of cutaneous homeostasis in regulating differentiation, proliferation, and inflammatory responses of the skin. PPAR agonists or antagonists may therefore, hold promise as interesting compounds for the treatment of various epidermal disorders characterized by inflammation, hyperproliferation and aberrant differentiation, such as psoriasis.

Keywords: peroxisome proliferator-activated receptors, differentiation, inflammation, proliferation, psoriasis

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2004
Published on: 01 March, 2012
Page: [205 - 211]
Pages: 7
DOI: 10.2174/1568010043343976
Price: $65

Article Metrics

PDF: 2